Actively Recruiting
A National Registry on Chinese Patients With Lymphangioleiomyomatosis
Led by Peking Union Medical College Hospital · Updated on 2021-09-24
1500
Participants Needed
1
Research Sites
508 weeks
Total Duration
On this page
Sponsors
P
Peking Union Medical College Hospital
Lead Sponsor
S
Shanghai Zhongshan Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.
CONDITIONS
Official Title
A National Registry on Chinese Patients With Lymphangioleiomyomatosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female gender
- No age limit
- Diagnosis of lymphangioleiomyomatosis (LAM) confirmed as definite or probable based on ATS/JRS and ERS criteria, or inclusion recommended by investigators
You will not qualify if you...
- Suspected LAM without supporting evidence
- Absence of diffuse cystic lung lesions
- Bilateral cystic lung lesions without established LAM diagnosis
- Lack of signed informed consent
- Difficulty in follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
K
Kai-Feng Xu, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here